NCT05626322TerminatedPhase 1/2
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION
Source: ClinicalTrials.gov · Last updated 5 Sept 2025
Reason given: The trial terminated due to the inability to recruit the planned number of subjects. The decision was not based on any safety and/or efficacy concerns
Brief summary (registry, in English)
The purpose of this study is to learn about the effects of three study medicines [maplirpacept (PF-07901801), tafasitamab, and lenalidomide] when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that: * is relapsed (has returned after last treatment) or * is refractory (has not responded to last treatment) DLBCL is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. This study is seeking participants who are unable or unwilling to undergo an autologous stem cell transplantation (when doctors put healthy blood cells back into your body) or CAR-T immune cell therapy. Everyone in this study will receive three medicines: maplirpacept (PF-07901801), tafasitamab and lenalidomide. Participants will receive maplirpacept (PF-07901801) and tafasitamab at the study clinic by intravenous (IV) infusion (given directly into a vein) and lenalidomide will be taken by mouth at home. Study interventions will be administered in 28-day cycles. Maplirpacept (PF-07901801) will be given weekly for the first three cycles and then every two weeks. Tafasitamab will administered on Days 1, 4, 8, 15 and 22 in cycle 1, weekly in cycles 2 and 3 and then every 2 weeks in cycle 4 and beyond. Lenalidomide will be taken every day for Days 1 to 21 of each 28-day cycle for the first 12 cycles. Participants can continue to take maplirpacept (PF-07901801) and tafasitamab until their lymphoma is no longer responding. Lenalidomide is discontinued after 12 cycles. Maplirpacept (PF-07901801) will be given at different doses to different participants. Everyone taking part will receive approved doses of tafasitamab and lenalidomide. We will compare the experiences of people receiving different doses of PF-07901801. This will help us to determine what dose is safe and effective when combined with the other 2 study medicines.
- Status (registry)
- Terminated
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- First submitted
- 15 Nov 2022
- Start date
- 4 Aug 2023
- Primary completion date
- 12 Aug 2024
- Lead sponsor
- Pfizer
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT05626322
- EU CT number
- 2022-502427-21-00
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with an anti-CD47 or anti-CD19 (other than CAR T) or immunomodulatory agents
- Prior allogeneic stem cell transplantation or autologous stem cell transplantation within 12 weeks prior to enrolment
Other illness
- Participants with active, uncontrolled bacterial, fungal or viral infection.
Who the study is looking for
- Histologically confirmed diagnosis of DLBCL
- Relapsed or refractory disease
- Participant is not be a candidate for or is unwilling to undergo high dose chemotherapy and subsequent stem cell transplant and/or is unable to receive chimeric antigen receptor (CAR) T-cell therapy
- Previous treatment with at least one prior line of systemic therapy (for phase 2, at least 1 and no more than 2 prior lines of systemic therapy). Prior therapy must include an anti-CD20 antibody.
- Adequate bone marrow, hepatic and renal function
- Eastern Cooperative Oncology Group (ECOG) ≤2
- Must provide a tumor tissue sample (fresh or archival, collected prior to start of treatment) for biomarker analysis
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yamagata University Hospital | Yamagata | Japan | Unknown status |
| Dong-A University Hospital | Busan | South Korea | Unknown status |
| Seoul National University Hospital | Seoul | South Korea | Unknown status |
| University of Michigan | Ann Arbor | United States | Unknown status |
| Mary Bird Perkins Cancer Center | Baton Rouge | United States | Unknown status |
| Lifespan Cancer Institute | Providence | United States | Unknown status |
| The Miriam Hospital | Providence | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.